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Abstract | Sixty years of intense fundamental research into T cell-mediated cytotoxicity have 
led to detailed knowledge of the cells involved, of specific recognition mechanisms, and of 
post-recognition perforin–granzyme-based and FAS-based molecular mechanisms. What 
could not be anticipated at the outset was how discovery of the mechanisms regulating the 
activation and function of cytotoxic T cells would lead to new developments in cancer 
immunotherapy. Given the profound recent interest in therapeutic manipulation of cytotoxic T 
cell responses, it is an opportune time to look back on the early history of the field. This 
Timeline describes how the early findings occurred, eventually leading to current therapeutic 
applications.  
 
Initially, scientists investigated cell-mediated cytotoxicity in their efforts to understand graft 
rejection. They also wondered why a cytotoxicity mechanism should have been evolutionarily 
selected in multicellular organisms, in which cytotoxic cells could kill only other cells of the 
same organism. This seemed to negate the fact that multicellularity depends on cooperation 
between cells. We now understand that cytotoxicity defends against those syngeneic [G] cells 
— either modified by oncogenesis or bearing intracellular infectious agents that are not 
otherwise reachable — whose death would benefit the whole multicellular organism. The 
same mechanisms are also thought to be involved in artificial conditions such as allograft 
rejection or in pathological circumstances such as in some autoimmune diseases. 
This Timeline article covers sixty years of fundamental research into T cell-mediated 
cytotoxicity, starting with early in vitro demonstrations of cell-mediated cytotoxicity, the 
quantification thereof and its attribution to T cells. This was followed by more analytical 
investigations, by which recognition of target cells was shown to involve specific T cell 
surface receptors, and post-recognition cytotoxicity was shown to be due to either a perforin- 
and granzyme-based mechanism or a FAS-based mechanism (FIG. 1). Importantly, we 
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believe that currently emerging therapeutic applications of T cell-mediated cytotoxicity, such 
as cancer immunotherapy, may benefit from a consideration of its mechanistic bases.  
Although natural killer (NK) cells and some CD4+ T cells are also endowed with 
cytotoxic activity, here we mainly discuss cytotoxicity mediated by ‘classical’ cytotoxic CD8+ 
T cells (also known as cytotoxic T lymphocytes (CTLs)), as has been studied most often in 
vitro. We focus on what we consider retrospectively to be the major advances in the field and 
apologize for the omission of many other excellent studies out of the several tens of thousands 
that have been published on this topic. 
 
[H1] Recognizing cytotoxicity: 1960s 
Pioneering experiments in the 1950s that aimed to find a mechanistic explanation for graft 
rejection assessed, mostly by microscopy, the cytolysis of donor tissue by sensitized lymphoid 
tissue in vitro. However, these experiments showed no evidence of cytotoxicity, perhaps 
because they were often carried out on donor explants rather than on isolated cells and also 
because they often aimed to show the participation of circulating antibodies and/or 
complement in these reactions (reviewed in REFS1-3). 
 
[H2] Early demonstrations of cytotoxicity. 
The first reports, in the 1960s, to show specific cytotoxicity in vitro used mostly allogeneic 
[G] combinations of cells. Thus, lymphocytes from dogs bearing a kidney homograft [G] 
produced specific lesions in donor kidney cultures, as visualized microscopically1. Similarly, 
lymphocytes from BALB/c mice alloimmunized with cells from C3H mice were shown to 
cluster on target cells of C3H origin and to induce their cytolysis. These target cells withdrew 
their processes and rounded up, with evidence of chromatin clumping that is suggestive, in 
retrospect, of apoptotic cell death2. Also, lymph node or thoracic duct lymphoid cells from 
allosensitized rodents were able to cluster around and destroy donor kidney cells in culture4.  
Cytotoxicity mediated by alloimmune mouse lymphoid cells could also be 
demonstrated by clonogenic assays [G]5 and through the inhibition of antibody plaque 
formation [G]6. Mouse alloimmune peritoneal cells — collected 10 days after an 
intraperitoneal injection of allogeneic tumour cells — comprising 3–5% lymphocytes showed 
strong immediate allospecific adherence and cytotoxicity to fibroblast monolayers, as 
demonstrated by the formation of clear plaques7. Cytotoxicity mediated by mouse alloimmune 
lymph node cells could be partially blocked by alloantibodies8. 
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In a xenogeneic [G] combination, lymphoid cells from mice immunized with human 
HeLa cells were cytotoxic to monolayers of HeLa cells9. Probably distinct from the above 
mechanisms, some target cells, such as L cells or embryonic fibroblasts, were shown to be 
sensitive to toxic substances (later defined as tumour necrosis factor or lymphotoxin) released 
by activated lymphocytes in an antigen-independent manner10,11. 
Other experiments were designed to mimick syngeneic autoimmune reactions, initially 
using interspecies immunization. Thus, lymph node cells from Lewis rats immunized with a 
suspension of guinea pig spinal cord were added to dog brain cells in vitro. These sensitized 
rat cells (but not non-sensitized cells) agglutinated around dog glial cells (but not dog 
fibroblasts) and destroyed them, thus demonstrating tissue-specific cytolysis in vitro12. 
Somewhat similarly, white blood cells or thoracic duct lymphocytes from rabbits or rats 
immunized with pig spinal cord agglutinated around and ultimately destroyed rat glial cells13. 
 
[H2] Quantifying cytotoxicity. 
By the mid-1960s, it was clear, at least qualitatively, that sensitized lymphoid cells  could 
lyse target cells in vitro. Further studies on the mechanisms of this cell-mediated cytotoxicity 
required better quantification. At about this time, several publications noted that the release 
from target cells of pre-incorporated radioisotopes, such as 32P orthophosphate or 14C amino 
acids, could be used as an indicator of cell damage 14,15.  
Most subsequent cytotoxicity experiments were carried out using the 51Cr release assay 
[G]. For nucleated target cells, this method was first used to evaluate the effect of antibodies 
in the presence of complement16–18 and was subsequently applied to cell-mediated 
cytotoxicity19,20. This method for assessing cytotoxicity had the advantages of being 
objective, short-term, accurate (early users were surprised by the low dispersal of 
experimental triplicates) and, because of the 51Cr half-life of 27 days and convenient gamma 
emission, more user-friendly than the use of other radiosiotopes such as 3H or 32P.  
The 51Cr release assay was extensively used until the mid-1990s and is now being 
progressively replaced, in particular for safety reasons, by non-radioactive methods. These 
include the release from dying target cells of lactate dehydrogenase (LDH), calcein or 
cytokeratin, the uptake by dying target cells of propidium iodide or similar normally cell-
impermeant dyes, the labeling in or on dying cells of activated caspases or exposed 
phosphatidylserine 21-23 and more sophisticated microscopy methods (see below). 
 
[H1] Identifying CTLs: 1970s 
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By the end of the 1960s, the accumulation of functional results on lymphoid cell-mediated 
cytotoxicity (reviewed in REF.24) and the emergence of appropriate methods to quantify such 
cytotoxicity enabled further analysis of the cells involved and their recognition mechanisms. 
 
[H2] T cells are required for anti-allogeneic cytotoxicity.  
Researchers were keen to discover which cells in particular are able to exert cytotoxicity in 
alloimmune spleen or lymph node cell populations. This was first investigated by treating 
such populations with T cell-specific antisera and then testing their residual cytotoxicity. In 
the presence of complement, but usually not in its absence, antisera such as anti-Thy1 
(REFS25-27), heterologous anti-T28 and most notably anti-Ly23 (REF.29) (Ly23 being later 
known as CD8) largely abolished subsequent anti-allogeneic cytotoxicity of mouse cells. This 
showed that such cytotoxicity requires T cells. 
 
[H2] T cells are sufficient for anti-allogeneic cytotoxicity. 
The demonstration that T cells are not only required but also sufficient for cytotoxicity was 
provided by using T cell-rich populations, such as thymus cells, that were allosensitized either 
in vivo or in vitro and then subjected to various methods for the depletion of non-T cells 
before testing for cytotoxicity25,27,28,30-33. A main conclusion from these studies was that a 
very small number of highly purified T cells were still able to exert cytotoxicity27, which 
makes it unlikely that non-T cells take part in the effector phase of T cell-mediated 
cytotoxicity. This autonomy of CTLs at the effector stage was consistent with the 
visualization of cell conjugates that often contain only one effector cell killing one target cell 
(see below). 
 
[H2] Early attempts to demonstrate specific surface receptors. 
Thus, by the early 1970s, it was clear that some T cells can autonomously induce target cell 
death. Analytical methods were then required to begin to dissect the mechanism(s) of this 
cytotoxicity. A good starting point was the hypothesis, discussed by D. Bernard Amos in the 
conclusion of an extensive review in 1962 (REF.3), that the specificity of cytotoxicity is the 
result of a specific recognition step (for example, through Paul Ehrlich's so-called ‘sessile 
antibodies’ on the cell surface) followed by non-specific cytotoxicity, rather than of 
specificity of the cytotoxic mechanism per se. Thus, specific recognition of target cells by 
CTLs putatively implied the existence of specific T cell surface receptors, which was also 
relevant to the then ongoing search for the T cell receptor for antigen34. Of note, columns of 
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antigen-coated beads retained antigen-specific B cells, thus demonstrating the existence of 
specific receptors for antigen at the B cell surface35, but could not retain antigen-specific T 
cells36. It was then realized that the recognition of antigen by T cells requires the presentation 
of this antigen through MHC molecules at the cell surface37-40; this was an important finding 
by itself and one of the key discoveries in T cell biology, and it also explained why antigen-
coated beads failed to specifically retain antigen-specific CTLs, whereas cell monolayer 
techniques (detailed below) succeeded. 
 
[H2] Specific adsorption of CTLs on cell monolayers. 
Early experiments, mentioned above, had already shown that sensitized lymphocyte 
populations contain cells that specifically aggregate on relevant cell monolayers. However, 
these results did not show that the aggregating cells were the same as the cytotoxic cells. A 
pioneering systematic investigation of this issue was carried out by Boris Brondz and 
colleagues, working in then relative isolation at the Gamaleya Institute in Moscow, initially in 
Lev A. Zilber's laboratory. Lymphocytes from in vivo alloimmunized mice, showing specific 
cytotoxicity in vitro against target cells bearing the immunizing H2 MHC antigens41, were 
incubated on macrophage monolayers and the non-adherent cells were then tested for specific 
cytotoxic activity. Cytotoxic activity of non-adherent cells was lost if incubation had been on 
monolayers bearing the immunizing H2 alloantigens, which strongly suggested that the 
cytotoxic cells were adsorbed on these monolayers because they bore surface receptors 
recognizing these antigens42. These studies also included investigations of the precise 
specificity of H2 congenic [G] alloreactions and their implications regarding the existence, 
nature and specificity of T cell receptors42,43 (reviewed in REF.44). One cannot be but 
impressed by Brondz' published work in terms of the quality of his experiments and 
discussion, in particular in the light of the few contacts that were available with Western 
scientists at that time. 
The specific loss of cytotoxic activity by adsorption of alloimmune mouse lymphocytes 
on relevant cell monolayers could be reproduced in a more convenient and quantitative 
manner soon afterwards using fibroblast monolayers and a 51Cr release assay45,46, also 
making use of highly purified T cells28. Moreover, after the incubation of alloimmune 
lymphocytes on relevant fibroblast monolayers, not only did non-adsorbed lymphocytes lose 
cytotoxicity, but also adsorbed lymphocytes could be recovered from the adsorbing 
monolayers and shown to be cytotoxic. This showed that the loss of cytotoxic activity of 
adherent cells was due to specific cell adsorption rather than specific inactivation45,46. The 
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existence of specific receptors for alloantigens was similarly demonstrated on normal mouse 
lymphocytes prior to sensitization47. Together, these experiments showed the existence of 
specific receptors for antigen at the surface of CTLs and their precursors. 
 
[H2] Specific CTL–target cell conjugates. 
Conjugates formed between one effector cell and one target cell could be obtained48 using 
tumour target cells and cytotoxic alloimmune lymphocytes from peritoneal exudate49. Study 
of these conjugates confirmed that a single CTL was required and sufficient to kill a target 
cell and that a CTL could recycle, which showed that effector cells do not die when killing 
target cells48. By microcinematography, sensitized lymphocytes were seen to approach the 
target cell, form a conjugate and then leave the target cell. The target cell burst after a delay, 
whereas the cell that had killed it was able to approach and kill other target cells50,51. Electron 
microscopy also showed the close apposition of effector and target cell membranes during 
conjugate formation51. 
 
[H2] Linking killing and dying. 
A striking observation made by Colin Sanderson using microcinematography was that, after 
being exposed to CTLs, dying target cells showed cell surface blebbing, which was distinct 
from the events that occur during complement-mediated lysis52 and similar to the apoptotic 
cell death that had recently been described in detail53. Importantly, this suggested that CTLs 
did not kill the target cells directly, but signalled to them to undergo cell death using their 
own self-destruction machinery 52. Also, if — as discussed above and in line with earlier 
results — the specific recognition of target cells and cell death signalling were separate steps, 
then these studies suggested that the post-recognition death signals need not be antigen 
specific. However, the death signals would need to somehow be polarized towards the target 
cells, as CTLs were not killed when killing target cells despite being sensitive to killing by 
other CTLs54. 
These and further more detailed phenomenological advances obtained through diverse 
analytical methods55,56 were abundantly reviewed at the time57-65. An important development 
during this period was the ability to clone CTLs66-68. These advances set the stage in the early 
1980s for researchers to begin to determine the post-recognition mechanism(s) that are 
involved in target cell killing (FIG. 2). 
 
[H1] Cytotoxic mechanisms: 1980s–1990s 
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Identification of post-recognition mechanisms was made possible in particular by the 
emergence at that time, in this field, of molecular biology approaches such as 
transfection, subtractive cDNA cloning and gene inactivation. 
[H2] The perforin–granzyme pathway. 
Microscopic observations provided a first hint as to the possible nature of a post-recognition 
mechanism of cytotoxicity. Tubular lesions were observed in target cell membranes after 
incubation with cytotoxic cells69,70 and also with purified granules from various types of 
cytotoxic cells71-73. A cytolytic protein known as perforin could be isolated from these 
granules74-77 and was found to be homologous to the ninth component of complement78. These 
important findings were in line with a granule-exocytosis model of cytotoxicity proposed by 
Pierre Henkart, who hypothesized that "target cell binding to a membrane receptor induces a 
secretory process in the effector cell in which the contents of cytoplasmic granules are 
released by local exocytosis between the effector cell and its bound target"75. Such a model 
implied that effector cell granules, containing perforin eventually together with other required 
molecules, were delivered to the target cell. The involvement of perforin in a major 
mechanism of cytotoxicity was confirmed a few years later by studies showing the marked 
decrease in cytotoxicity mediated by CTLs transfected with perforin antisense material79 or 
CTLs from perforin-knockout mice80,81. 
However, CTLs had been shown previously to induce apoptosis, whereas purified 
perforin induced a different type of cell death similar to necrosis. This suggested at the time 
that perforin could not be the only effector molecule of target cell death and that it had to 
function in association with other molecules to induce apoptosis. Serine-esterases were likely 
candidates, as serine-esterase inhibitors inhibited T cell-mediated cytotoxicity82,83. Indeed 
serine-esterases could be biochemically isolated from CTLs84-87 and moreover were localized 
in their granules88-90, hence being named ‘granzymes’. 
Granzymes were independently identified through a subtractive cDNA cloning 
approach, based on the rationale that some of the molecules involved in cytotoxicity may be 
expressed only in cytotoxic cells. Such molecules with a restricted tissue distribution were 
identified by subtracting mRNAs from non-cytotoxic cells from CTL mRNAs, and cloning 
the resulting material (reviewed in REF.91). This led to the identification of CTLA3 
(REFS92,93), which was identical to the independently identified Hanuka factor94 and 
granzyme A; and of CTLA1 (REF.92), which was identical to the independently identified 
CCP1 (REF.95) and granzyme B.  
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The role of granzymes in cytotoxicity was not easy to formally establish through gene 
inactivation because of functional redundancy. However, such a role was strongly suspected 
on the basis of, in particular, the apoptosis-like cytotoxicity that was observed in perforin–
granzyme co-transfection experiments96-98. It later became clear that, usually with the help of 
perforin, effector cell granzymes can activate distinct death pathways within the target cell 
and can have multiple roles99-103. 
 
[H2] The perforin-granzyme pathway does not fully account for cytotoxicity. 
Thus, by the late 1980s, a major granule exocytosis mechanism of CTL-mediated cytotoxicity 
was strongly suspected to involve both perforin and granzymes, first localized within CTL 
granules, then somehow exocytosed, to enter the target cell and cause its death by triggering 
apoptosis. However, in parallel, arguments were lining up to suggest that this mechanism did 
not fully account for cytotoxicity. For example, peritoneal exudate lymphocytes that seemed 
to lack both granules and significant levels of perforin expression were highly cytotoxic104, 
which lead researchers to discuss alternative explanations for cytotoxicity including, in 
particular, cell surface death receptors105. Also, granule exocytosis and perforin-based 
cytotoxicity required Ca2+, but part of the cytotoxic activity of CTL populations or clones was 
found to be independent of extracellular Ca2+ (REFS106-110). 
Scientific meetings discussing cytotoxicity were particularly lively at that time, with 
heated controversies between proponents of perforin-only, not-only-perforin and no-perforin 
mechanisms. Even written comments on this debate had less-than-detached titles111. 
 
[H2] Identifying the FAS pathway. 
If CTLs were indeed using two distinct mechanisms of cytotoxicity, then studying one of 
these mechanisms might benefit from excluding the other. One way to achieve this was to 
attempt to delete the known granule exocytosis mechanism from CTLs, for example through 
loss of genetic material. The PC60 T cell hybridoma initially derived by Markus Nabholz, 
which was constitutive for growth and inducible for cytotoxicity upon addition of 
interleukins112, seemed a good starting point. PC60 is a heterospecific hybridoma between rat 
and mouse cells, and it was known that such hybridomas tend to randomly loose mouse or rat 
chromosomes. PC60 cells were grown in long-term culture and periodically cloned by 
limiting dilution (described in detail in REF.113). These clones were tested for their 
cytotoxicity against various target cells, with the clone showing highest levels of cytotoxicity 
being expanded, tested cytogenetically, grown again for several months, then cloned again, 
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and so on. This process was repeated for several years, leading to a tenth-generation PC60-
d10S derivative. These d10S cells had lost about 20 chromosomes from the initial sum of the 
parental chromosomes. They showed non-MHC-restricted, Ca2+-independent cytotoxicity. 
When d10S cells were tested against a range of target cells, thymocytes were particularly 
sensitive114.  
While these results were being obtained, a striking report by Shigekazu Nagata and 
colleagues115 mentioned that FAS (also known as APO-1 or CD95), a known cell-death-
transducing surface molecule116,117, was abundantly expressed on thymocytes of wild-type 
mice but was not detectably expressed in lpr mice [G]115. These results led to speculation that 
FAS could be involved in d10S-mediated cytotoxicity and offered a way to test this 
hypothesis. Indeed, whereas wild-type mouse thymocytes were sensitive to d10S-mediated 
cytotoxicity, lpr mouse thymocytes were not. Also, FAS-negative tumour target cells became 
sensitive to cytotoxic killing by d10S cells upon transfection of FAS114. This FAS-based 
mechanism of cytotoxicity was not limited to PC60-d10S cells, as the Ca2+-independent 
component106,107 of antigen-specific cytotoxicity mediated by alloimmune peritoneal exudate 
cells lysed FAS-bearing, but not FAS-deficient, target cells114. In the summer of 1992, the 
report describing these results was rejected by Nature, but it was rapidly accepted elsewhere 
and published in January 1993 (REF.114). These results showed that a mechanism of T cell-
mediated cytotoxicity was FAS dependent. 
 
[H2] Two pathways for cytotoxicity, and identification of the FAS ligand. 
These results were further developed in two directions. First, in terms of cytotoxicity, it was 
shown that CTLs from perforin-knockout mice could still lyse target cells, through the FAS 
pathway, and that target cells from lpr mice could still be lysed by the perforin–granzyme 
pathway but, importantly, could not be lysed by perforin-knockout effector cells. These and 
other similar experiments showed that only two main mechanisms accounted for T cell-
mediated cytotoxicity, namely the perforin–granzyme-dependent granule exocytosis 
mechanism and the FAS-mediated mechanism118-121.  
Second, at that time several groups were trying to identify the ligand for FAS. It was 
reasoned that d10S cells, which exerted cytotoxicity through FAS expressed on target cells, 
must bear a ligand for FAS. The Nagata laboratory used a FAS-Fc construct to further FACS-
select d10S cell derivatives overexpressing the putative FAS ligand. They succeeded to clone 
the FAS ligand (FASL; also known as CD95L) from these cells by expression cloning and 
published the corresponding report in December 1993, within one year of receiving the d10S 
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cells122. These and other early developments of FAS research were extensively reviewed at 
the time (for example, see REF.123). Further studies showed that the perforin–granzyme 
pathway seems to be the dominant pathway for killing infected or transformed cells, whereas 
the FAS pathway seems to be more involved in regulating lymphocyte homeostasis124. 
Altogether, by the mid-1990s, the broad outlines of the FAS-based and the perforin–
granzyme-based mechanisms by which CTLs can induce target cell death had been 
established. As a consequence, these years constituted a turning point for researchers in the 
field. Some turned to the study of cell death per se, whereas others went on studying, in 
greater molecular detail, the mechanisms of CTL-mediated cytotoxicity (FIG. 2). 
 
[H1] Perforin-granzyme cytotoxicity: 1990s 
In CD8+ T cells, the expression of perforin, granzymes and FASL was shown to be 
upregulated by, in particular, the transcription factors BLIMP1, eomesodermin and T-bet, 
through CD4+ T cell help in conjunction with changes to T cell metabolism (reviewed in 
REFS125-128). As revealed by immuno-electron microscopy in both NK cells and CTLs, 
perforin and granzymes co-localize with lysosomal hydrolases in a dual-function organelle 
that functions as both a lysosome and a secretory granule, being known as a secretory 
lysosome129,130. This raised the interesting question of how CTLs have evolved to turn a 
lysosome into a secretory organelle. A key finding emerged from genetic analysis of the 
primary immunodeficiency haemophagocytic lymphohistiocytosis [G] (HLH), which is a 
rapidly fatal disease in which CTLs are unable to kill. Importantly, not only mutations in 
perforin131, but also in other molecules132, led to HLH. The latter mutations were in genes 
encoding the proteins RAB27A, UNC13D (also known as MUNC13-4), syntaxin 11 and 
MUNC18-2 (also known as STXBP2)132, which are required for secretion of the modified 
CTL lysosome. 
An early indication of how CTL activation leads to granule secretion was provided by 
the observation of an increase in cytosolic Ca2+ upon target cell recognition133. Following 
early observations in CTLs and NK cells of polarization of the Golgi apparatus and the 
microtubule-organizing centre towards target cells134-136, confocal imaging revealed the 
remarkable reorganization of receptors that occurs at the interface between T cells and 
antigen-presenting cells 137. This led to the discovery of a specialized secretory domain within 
the corresponding ‘immunological synapse’ of CTLs, where cytolytic granules deliver their 
cargo to target cells138. Further studies revealed a novel role for the centrosome in docking 
directly with the plasma membrane at the immunological synapse, thereby focusing secretion 
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at the point of TCR signalling139 and ensuring that only the recognized target cells are killed. 
Ultimately, the granule contents — including perforin, granzymes and also the antimicrobial 
peptide granulysin (expressed in humans, but not rodents) — ended up in the intercellular 
cleft between the CTL and target cell. 
At the level of the target cell, perforin was required but not sufficient for lysis. 
Perforin was shown to facilitate access to the cytosol of death-triggering granzymes, by 
forming pores at the cell membrane96,140. Several granzymes could induce apoptosis, but 
granzyme B seemed to be the most efficient by targeting caspases either directly or through 
the pro-apoptotic protein BID 101. Several granzymes could also lead to non-apoptotic forms 
of cell death99. Moreover, granzymes and granulysin could target and destroy intracellular 
parasites141-144. 
 
[H1] FAS-based cytotoxicity: mid-1990s 
One puzzle regarding FAS-based killing arose from the observation that FASL activity was 
rapidly inactivated by metalloprotease cleavage of the extracellular domain at the plasma 
membrane 145. Although this showed that FASL activity required membrane association and 
revealed a clear mechanism for down-regulation of FAS-mediated killing, it also raised the 
question of how FASL might be active even transiently once at the plasma membrane. One 
possible answer is that FASL is packaged within cytotoxic granules in CTLs and NK cells146. 
Moreover, ubiquitylation signals in the cytosolic tail of FASL target it to intraluminal vesicles 
within such cytotoxic granules147, which is consistent with the observation of FASL activity 
within vesicle preparations148. Thus, FASL is found in intraluminal vesicles that surround the 
perforin-containing dense core within cytotoxic granules149. FASL-bearing vesicles would be 
released from cytotoxic granules upon secretion into the small cleft formed between the CTL 
and the FAS-bearing target cell to provide highly focused FASL-mediated killing. 
In the target cell, as a FASL-constrained functional trimer150, FAS was shown to 
signal to FAS-associated death domain protein (FADD)151, leading to caspase 8 activation152 
then caspase 3 activation and apoptosis. FAS-induced signalling was shown to be regulated in 
part by molecular recruitment to membrane rafts153 and by post-translational modifications154. 
FAS signalling also induced various functions in addition to cell death155-158. The 
lymphadenopathy that is prominent in mouse and human159 mutants of the FAS pathway 
indicates that a main function of this pathway is to regulate the immune system, classically 
through the control of lymphocyte death although other mechanisms have been 
proposed158,160.  
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[H1] CTLs and therapy 
The knowledge that was accumulated over many years of research on T cell-mediated 
cytotoxicity started to lead to therapeutic applications, for example through the molecular 
definition of the cytotoxicity mutants described above. In parallel, other developments were 
taking place that also turned out to be relevant to the role of CTLs in therapy. Perforin-
deficient mice were shown to be more susceptible than wild-type mice to carcinogenesis, 
which implicated the immune system, and more precisely CTLs, in cancer 
immunosurveillance161,162. Cancer immunotherapy was attempted using IL-2-activated 
lymphocytes163. In 1987, the immune checkpoint molecule cytotoxic T lymphocyte antigen 4 
(CTLA4) was isolated through subtractive cDNA cloning91,164, and about 5 years later another 
checkpoint molecule, programmed cell death protein 1 (PD1), was similarly identified165. 
Ctla4-knockout mice166,167 and humans with CTLA4 mutations168,169 have similar 
lymphoproliferative phenotypes, which showed that CTLA4 has an inhibitory effect on 
lymphoid cells. Similarly, although not exactly the same, Pd1-knockout mice had 
splenomegaly, abnormalities of B cell proliferation and differentiation170 and lupus-like 
autoimmune disease171, which suggested that PD1 maintains peripheral self-tolerance by 
negatively regulating immune responses172. The different phenotypyes resulting from CTLA4 
or PD1 deficiency or mutation reflect the fact that they function, at least in part, at distinct 
steps and also on distinct T cell subsets173. If CTLA4 and PD1 negatively regulate the 
activation of CTLs, contributing to their exhaustion174, then it was proposed that interfering 
with these molecules, using for example specific antibodies, could (re)activate CTLs to help 
eliminate or at least control tumour growth. Indeed, in tumour-bearing mice, antibodies 
directed against CTLA4 (REF.175) or the PD1–PDL1 pathway176,177 could lead to tumour 
regression. Striking remissions were observed in a minority of patients with melanoma who 
were treated with antibodies against CTLA4 (REF.178) or PD1 (REFS179,180). Many clinical 
trials using such antibodies to treat other types of cancer are underway 181. Although the 
possibility has not yet been fully explored, CTL activation using antibodies against such 
inhibitory checkpoint molecules may also have potential to be used to fight viral, bacterial 
and parasitic infections182,183. 
The alternative possibility arising from the discovery of checkpoint molecules was the 
ability to decrease CTL activity in certain therapeutic or pathological circumstances. Soluble 
CTLA4–Fc constructs can engage CD80 and CD86 (which are ligands of both CTLA4 and 
CD28) with high affinity, leading to inhibition of the CD28-mediated co-stimulation pathway 
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and consequent inhibition of CTL activation184,185. Such constructs were indeed shown to be 
efficient against some autoimmune diseases186 and against graft rejection187,188. A possible 
similar use of PD1 agonists is also being considered189. 
CTLs have also been effectively harnessed in other ways to control cancer. Instead of 
activating endogenous CTLs through the use of injected antibodies as described above, CTLs 
themselves can be injected into a patient190, in particular after their transfection with genes 
encoding chimeric antigen receptors (CARs) 191,192. These CARs consist of an antibody-
derived targeting fragment together with signalling domains that can activate T cells. Ideally, 
the antibody-derived fragment is selected to recognize, in an MHC-independent manner, an 
antigen that is present at the surface of cancer cells but not healthy cells. The signalling 
domains thus lead to activation of the CTLs, which then induce cancer cell death. Such CAR 
T cells have already shown striking efficacy at controlling some haematological 
malignancies193. 
 
[H1] Conclusions 
Sixty years of research have led to the characterization of CTLs and mechanistic investigation 
of their cytotoxic effects. Perhaps the most thought-provoking result of these studies has been 
the realization that CTLs most often kill target cells by inducing signalling through the same 
apoptotic pathway that is used for developmental cell death. Within the past 30 years, further 
molecular investigations have led to existing or promising potential clinical applications for 
some genetic diseases, autoimmune and infectious diseases and graft rejection, and perhaps 
most importantly for cancer immunotherapy using CTLs as a therapeutic tool. Research in the 
field of CTLs may now have reached the point where it is has progressed beyond basic 
science and is dominated by medical applications, hopefully leading to further exciting 
therapeutic advances. 
 
REFERENCES  
1 Govaerts, A. Cellular antibodies in kidney homotransplantation. J. Immunol. 85, 516-
522 (1960). 
2 Rosenau, W. & Moon, H. D. Lysis of homologous cells by sensitized lymphocytes in 
tissue culture. J. Natl Cancer Inst. 27, 471-483 (1961). 
3 Amos, D. B. The use of simplified systems as an aid to the interpretation of 
mechanisms of graft rejection. Prog. Allergy 6, 468-538 (1962). 
 14
4 Wilson, D. B. The Reaction of Immunologically Activated Lymphoid Cells against 
Homologous Lymphoid Cells against Homologous Target Tissue Cells in Vitro. J. Cell. Comp. 
Physiol. 62, 273-286 (1963). 
5 Brunner, K. T., Mauel, J. & Schindler, R. In vitro studies of cell-bound immunity ; 
cloning assay of the cytotoxic action of sensitized lymphoid cells on allogeneic target cells. 
Immunology 11, 499-506 (1966). 
6 Friedman, H. Inhibition of Antibody Plaque Formation by Sensitized Lymphoid Cells: 
Rapid Indicator of Transplantation Immunity. Science 145, 607-609 (1964). 
7 Granger, G. A. & Weiser, R. S. Homograft target cells : specific destruction in vitro by 
contact interaction with immune macrophages. Science 145, 1427-1429 (1964). 
8 Möller, E. Antagonistic effects of humoral isoantibodies on the in vitro cytotoxicity of 
immune lymphoid cells. J. Exp. Med. 122, 11-23 (1965). 
9 Stuart, A. E. The cytotoxic effect of heterologous lymphoid cells. Lancet 2, 180-182 
(1962). 
10 Granger, G. A. & Williams, T. W. Lymphocyte cytotoxicity in vitro : activation and 
release of a cytotoxic factor. Nature 218, 1253-1254 (1968). 
11 Ruddle, N. H. & Waksman, B. H. Cytotoxicity mediated by soluble antigen and 
lymphocytes in delayed hypersensitivity. III. Analysis of mechanism. J. Exp. Med. 128, 1267-
1279 (1968). 
12 Koprowski, H. & Fernandes, M. V. Autosensitization reaction in vitro. Contactual 
agglutination of sensitized lymph node cells in brain tissue culture accompanied by 
destruction of glial elements. J. Exp. Med. 116, 467-476 (1962). 
13 Berg, O. & Kallen, B. White blood cells from animals with experimental allergic 
encephalomyelitis tested on glia cells in tissue culture. Acta Pathol. Microbiol. Scand. 58, 33-
42 (1963). 
14 Perlmann, P. & Broberger, O. In vitro studies of ulcerative colitis. II. Cytotoxic action 
of white blood cells from patients on human fetal colon cells. J. Exp. Med. 117, 717-733 
(1963). 
15 Vainio, T., Koskimies, O., Perlmann, P., Perlmann, H. & Klein, G. In vitro cytotoxic 
effect of lymphoid cells from mice immunized with allogeneic tissue. Nature 204, 453-455 
(1964). 
 15
16 Sanderson, A. R. Cytotoxic Reactions of Mouse Iso-Antisera: Preliminary 
Considerations. Br. J. Exp. Pathol. 45, 398-408 (1964). 
17 Sanderson, A. R. Applications of Iso-Immune Cytolysis Using Radiolabelled Target 
Cells. Nature 204, 250-253 (1964). 
18 Wigzell, H. Quantitative Titrations of Mouse H-2 Antibodies Using Cr-51-Labelled 
Target Cells. Transplantation 3, 423-431 (1965). 
19 Holm, G. & Perlmann, P. Quantitative studies on phytohaemagglutinin-induced 
cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology 
12, 525-536 (1967). 
20 Brunner, K. T., Mauel, J., Cerottini, J.-C. & Chapuis, B. Quantitative assay of the lytic 
action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro ; inhibition 
by isoantibody and by drugs. Immunology 14, 181-196 (1968). 
21 Henry, C. M., Hollville, E. & Martin, S. J. Measuring apoptosis by microscopy and flow 
cytometry. Methods 61, 90-97 (2013). 
22 Frick, M. et al. Distinct patterns of cytolytic T-cell activation by different tumour cells 
revealed by Ca2+ signalling and granule mobilization. Immunology 150, 199-212 (2017). 
23 Vanden Berghe, T. et al. Determination of apoptotic and necrotic cell death in vitro 
and in vivo. Methods 61, 117-129 (2013). 
24 Perlmann, P. & Holm, G. Cytotoxic effects of lymphoid cells in vitro. Adv.Immunol. 11, 
117-193 (1969). 
25 Cerottini, J.-C., Nordin, A. A. & Brunner, K. T. Specific in vitro cytotoxicity of thymus-
derived lymphocytes sensitized to alloantigens. Nature 228, 1308-1309 (1970). 
26 Lonai, P., Clark, W. R. & Feldman, M. Participation of theta-bearing cell in an in vitro 
assay of transplantation immunity. Nature 229, 566-567 (1971). 
27 Golstein, P. & Blomgren, H. Further evidence for autonomy of T cells mediating 
specific in vitro cytotoxicity : efficiency of very small amounts of highly purified T cells. Cell. 
Immunol. 9, 127-141 (1973). 
28 Golstein, P., Wigzell, H., Blomgren, H. & Svedmyr, E. A. Cells mediating specific in 
vitro cytotoxicity. II. Probable autonomy of thymus-processed lymphocytes (T cells) for the 
killing of allogeneic target cells. J. Exp. Med. 135, 890-906 (1972). 
 16
29 Cantor, H. & Boyse, E. A. Functional subclasses of T-lymphocytes bearing different Ly 
antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative 
process independent of antigen. J. Exp. Med. 141, 1376-1389 (1975). 
30 Golstein, P., Wigzell, H., Blomgren, H. & Svedmyr, E. A. J. Autonomy of thymus-
processed lymphocytes ( T cells ) for their education into cytotoxic T cells. Eur. J. Immunol. 2, 
498-501 (1972). 
31 Sprent, J. & Miller, J. F. Activation of thymus cells by histocompatibility antigens. Nat. 
New Biol. 234, 195-198 (1971). 
32 Blomgren, H. & Svedmyr, E. In vitro stimulation of mouse thymus cells by PHA and 
allogeneic cells. Cell. Immunol. 2, 285-299 (1971). 
33 Lohmann-Matthes, M. L. & Fischer, H. Specific cytotoxicity of a mouse thymocyte 
population sensitized in vitro against H-2 alloantigens. Eur. J. Immunol. 2, 290-292 (1972). 
34 Crone, M., Koch, C. & Simonsen, M. The elusive T cell receptor. Transplant. Rev. 10, 
36-56 (1972). 
35 Wigzell, H. & Andersson, B. Cell separation on antigen-coated columns. Elimination of 
high rate antibody-forming cells and immunological memory cells. J. Exp. Med. 129, 23-36 
(1969). 
36 Wigzell, H. Specific fractionation of immunocompetent cells. Transplant. Rev. 5, 76-
104 (1970). 
37 Kindred, B. & Shreffler, D. C. H-2 dependence of co-operation between T and B cells 
in vivo. J. Immunol. 109, 940-943 (1972). 
38 Katz, D. H., Hamaoka, T., Dorf, M. E. & Benacerraf, B. Cell interactions between 
histoincompatible T and B lymphocytes. The H-2 gene complex determines successful 
physiologic lymphocyte interactions. Proc. Natl Acad. Sci. U S A. 70, 2624-2628 (1973). 
 
39 Shearer, G. M. Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic 
lymphocytes. Eur. J. Immunol. 4, 527-533 (1974). 
40 Zinkernagel, R. M. & Doherty, P. C. Restriction of in vitro T cell-mediated cytotoxicity 
in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 
701-702 (1974). 
41 Brondz, B. D. Interaction of immune lymphocytes in vitro with normal and neoplastic 
tissue cells. Folia Biol. 10, 164-175 (1964). 
 17
42 Brondz, B. D. Complex specificity of immune lymphocytes in allogeneic cell cultures. 
Folia Biol. 14, 115-131 (1968). 
43 Brondz, B. D. & Snegirova, A. E. Interaction of immune lymphocytes with the mixtures 
of target cells possessing selected specificities of the H-2 immunizing allele. Immunology 20, 
457-468 (1971). 
44 Brondz, B. D. Lymphocyte receptors and mechanisms of in vitro cell-mediated 
immune reactions. Transplant. Rev. 10, 112-151 (1972). 
45 Golstein, P., Svedmyr, E. A. J. & Wigzell, H. Cells mediating specific in vitro 
cytotoxicity. I. Detection of receptor-bearing lymphocytes. J. Exp. Med. 134, 1385-1402 
(1971). 
46 Berke, G. & Levey, R. H. Cellular immunoabsorbents in transplantation immunity. 
Specific in vitro deletion and recovery of mouse lymphoid cells sensitized against allogeneic 
tumors. J. Exp. Med. 135, 972-984 (1972). 
47 Altman, A., Cohen, I. R. & Feldman, M. Normal T-cell receptors for alloantigens. Cell. 
Immunol. 7, 134-142 (1973). 
48 Zagury, D., Bernard, J., Thiernesse, N., Feldman, M. & Berke, G. Isolation and 
characterization of individual functionally reactive cytotoxic T lymphocytes : conjugation, 
killing and recycling at the single cell level. Eur. J. Immunol. 5, 818-822 (1975). 
49 Berke, G., Sullivan, K. A. & Amos, B. Rejection of ascites tumor allografts. I. Isolation, 
characterization, and in vitro reactivity of peritoneal lymphoid effector cells from BALB/c 
mice immune to EL4 leukosis. J. Exp. Med. 135, 1334-1350 (1972). 
50 Ax, W., Malchow, H., Zeiss, I. & Fischer, H. The behaviour of lymphocytes in the 
process of target cell destruction in vitro. Exp. Cell Res. 53, 108-116 (1968). 
51 Koren, H. S., Ax, W. & Freund-Moelbert, E. Morphological observations on the 
contact-induced lysis of target cells. Eur. J. Immunol. 3, 32-37 (1973). 
52 Sanderson, C. J. The mechanism of T cell mediated cytotoxicity. II. Morphological 
studies of cell death by time-lapse microcinematography. Proc. R. Soc. Lond. B Biol. Sci. 192, 
241-255 (1976). 
53 Kerr, J. F. R., Wyllie, A. H. & Currie, A. R. Apoptosis : a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Brit. J. Cancer 26, 239-257 (1972). 
54 Golstein, P. Sensitivity of cytotoxic T cells to T cell-mediated cytotoxicity. Nature 252, 
81-83 (1974). 
 18
55 Wagner, H. & Röllinghoff, M. T cell-mediated cytotoxicity : Discrimination between 
antigen recognition, lethal hit and cytolysis phase. Eur. J. Immunol. 4, 745-750 (1974). 
56 Gately, M. K. & Martz, E. Early steps in specific tumor cell lysis by sensitized mouse T 
lymphocytes. III. Resolution of two distinct roles for calcium in the cytolytic process. J. 
Immunol. 122, 482-489 (1979). 
57 Cerottini, J.-C. & Brunner, K. T. Cell-mediated cytotoxicity, allograft rejection, and 
tumor immunity. Adv.Immunol. 18, 67-132 (1974). 
58 Henney, C. S. T-cell-mediated cytolysis : an overview of some current issues. 
Contemp. Top. Immunobiol. 7, 245-272 (1977). 
59 Martz, E. Mechanism of specific tumor-cell lysis by alloimmune T lymphocytes : 
resolution and characterization of discrete steps in the cellular interaction. Contemp. Top. 
Immunobiol. 7, 301-361 (1977). 
60 Golstein, P. & Smith, E. T. Mechanism of T-cell-mediated cytolysis: the lethal hit 
stage. Contemp. Top. Immunobiol. 7, 273-300 (1977). 
61 Sanderson, C. J. The mechanism of lymphocyte-mediated cytotoxicity. Biol. Rev. 
Camb. Philos. Soc. 56, 153-197 (1981). 
62 Bonavida, B. et al. Molecular interactions in T-cell-mediated cytotoxicity. Immunol. 
Rev. 72, 119-141 (1983). 
63 Russell, J. H. Internal disintegration model of cytotoxic lymphocyte-induced target 
damage. Immunol. Rev. 72, 97-118 (1983). 
64 Martz, E., Heagy, W. & Gromkowski, S. H. The mechanism of CTL-mediated killing: 
monoclonal antibody analysis of the roles of killer and target-cell membrane proteins. 
Immunol. Rev. 72, 73-96 (1983). 
65 Berke, G. Cytotoxic T-lymphocytes. How do they function? Immunol. Rev. 72, 5-42 
(1983). 
66 Baker, P. E., Gillis, S. & Smith, K. A. Monoclonal cytolytic T-cell lines. J. Exp. Med. 149, 
273-278 (1979). 
67 Nabholz, M. et al. Established murine cytolytic T-cell lines as tools for a somatic cell 
genetic analysis of T-cell functions. Immunol. Rev. 51, 125-156 (1980). 
68 Albert, F., Buferne, M., Boyer, C. & Schmitt-Verhulst, A.-M. Interactions between 
MHC-encoded products and cloned T cells.I. Fine specificity for induction of proliferation and 
lysis. Immunogenetics 16, 533-549 (1982). 
 19
69 Dourmashkin, R. R., Deteix, P., Simone, C. B. & Henkart, P. Electron microscopic 
demonstration of lesions in target cell membranes associated with antibody-dependent 
cellular cytotoxicity. Clin. Exp. Immunol. 42, 554-560 (1980). 
70 Dennert, G. & Podack, E. R. Cytolysis by H-2-specific T killer cells. Assembly of tubular 
complexes on target membranes. J. Exp. Med. 157, 1483-1495 (1983). 
71 Criado, M., Lindstrom, J. M., Anderson, C. G. & Dennert, G. Cytotoxic granules from 
killer cells: specificity of granules and insertion of channels of defined size into target 
membranes. J. Immunol. 135, 4245-4251 (1985). 
72 Podack, E. R. & Konigsberg, P. J. Cytolytic T cell granules. Isolation, structural, 
biochemical, and functional characterization. J. Exp. Med. 160, 695-710 (1984). 
73 Henkart, P. A., Millard, P. J., Reynolds, C. W. & Henkart, M. P. Cytolytic activity of 
purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J. Exp. 
Med. 160, 75-93 (1984). 
74 Podack, E. R., Young, J. D.-E. & Cohn, Z. A. Isolation and biochemical and functional 
characterization of perforin 1 from cytolytic T-cell granules. Proc. Natl Acad. Sci. U S A. 82, 
8629-8633 (1985). 
75 Henkart, P. A. Mechanism of lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 
3, 31-58 (1985). 
76 Masson, D. & Tschopp, J. Isolation of a lytic, pore-forming protein ( perforin ) from 
cytolytic T lymphocytes. J. Biol. Chem. 260, 9069-9072 (1985). 
77 Young, J. D.-E., Hengartner, H., Podack, E. R. & Cohn, Z. A. Purification and 
characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes 
with natural killer activity. Cell 44, 849-859 (1986). 
78 Shinkai, Y., Takio, K. & Okumura, K. Homology of perforin to the ninth component of 
complement (C9). Nature 334, 525-527 (1988). 
79 Acha-Orbea, H., Scarpellino, L., Hertig, S., Dupuis, M. & Tschopp, J. Inhibition of 
lymphocyte mediated cytotoxicity by perforin antisense oligonucleotides. EMBO J. 9, 3815-
3819 (1990). 
80 Kägi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly 
impaired in perforin-deficient mice. Nature 369, 31-37 (1994). 
 20
81 Lowin, B., Beermann, F., Schmidt, A. & Tschopp, J. A null mutation in the perforin 
gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc. Natl 
Acad. Sci. U S A. 91, 11571-11575 (1994). 
82 Chang, T. W. & Eisen, H. N. Effects of N-«-tosyl-L-lysyl-chloromethylketone on the 
activity of cytotoxic T lymphocytes. J. Immunol. 124, 1028-1033 (1980). 
83 Redelman, D. & Hudig, D. The mechanism of cell-mediated cytotoxicity.I. Killing by 
murine cytotoxic T lymphocytes requires cell surface thiols and activated proteases. J. 
Immunol. 124, 870-878 (1980). 
84 Pasternack, M. S. & Eisen, H. N. A novel serine esterase expressed by cytotoxic T 
lymphocytes. Nature 314, 743-745 (1985). 
85 Pasternack, M. S., Verret, C. R., Liu, M. A. & Eisen, H. N. Serine esterase in cytolytic T 
lymphocytes. Nature 322, 740-743 (1986). 
86 Kramer, M. D. et al. Characterization and isolation of a trypsin-like serine protease 
from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells. 
J. Immunol. 136, 4644-4651 (1986). 
87 Simon, M. M., Hoschützky, H., Fruth, U., Simon, H.-G. & Kramer, M. D. Purification 
and characterization of a T cell specific serine proteinase ( TSP-1 ) from cloned cytolytic T 
lymphocytes. EMBO J. 5, 3267-3274 (1986). 
88 Young, J. D.-E. et al. Isolation and characterization of a serine esterase from cytolytic 
T cell granules. Cell 47, 183-194 (1986). 
89 Masson, D., Nabholz, M., Estrade, C. & Tschopp, J. Granules of cytolytic T-
lymphocytes contain two serine esterases. EMBO J. 5, 1595-1600 (1986). 
90 Masson, D. & Tschopp, J. A family of serine esterases in lytic granules of cytolytic T 
lymphocytes. Cell 49, 679-685 (1987). 
91 Brunet, J.-F., Denizot, F. & Golstein, P. A differential molecular biology search for 
genes preferentially expressed in functional T lymphocytes : the CTLA genes. Immunol. Rev. 
103, 21-36 (1988). 
92 Brunet, J.-F. et al. The inducible cytotoxic-T-lymphocyte-associated gene transcript 
CTLA-1 sequence and gene localization to mouse chromosome 14. Nature 322, 268-271 
(1986). 
93 Brunet, J.-F. et al. CTLA-1 and CTLA-3 serine-esterase transcripts are detected mostly 
in cytotoxic cells, but not only and not always. J.Immunol. 138, 4102-4105 (1987). 
 21
94 Gershenfeld, H. K. & Weissman, I. L. Cloning of a cDNA for a T cell-specific serine 
protease from a cytotoxic T lymphocyte. Science 232, 854-858 (1986). 
95 Lobe, C. G., Finlay, B. B., Paranchych, W., Paetkau, V. H. & Bleackley, R. C. Novel 
serine proteases encoded by two cytotoxic T lymphocyte-specific genes. Science 232, 858-
861 (1986). 
96 Shiver, J. W., Su, L. & Henkart, P. A. Cytotoxicity with target DNA breakdown by rat 
basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 71, 315-322 (1992). 
97 Shi, L., Kam, C.-M., Powers, J. C., Aebersold, R. & Greenberg, A. H. Purification of 
three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct 
substrate and target cell interactions. J. Exp. Med. 176, 1521-1529 (1992). 
98 Shi, L., Kraut, R. P., Aebersold, R. & Greenberg, A. H. A natural killer cell granule 
protein that induces DNA fragmentation and apoptosis. J. Exp. Med. 175, 553-566 (1992). 
99 Chowdhury, D. & Lieberman, J. Death by a thousand cuts: granzyme pathways of 
programmed cell death. Annu. Rev. Immunol. 26, 389-420 (2008). 
100 Ewen, C. L., Kane, K. P. & Bleackley, R. C. A quarter century of granzymes. Cell Death 
Differ. 19, 28-35 (2012). 
101 Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, 
dysfunction and human pathology. Nat. Rev. Immuno.l 15, 388-400 (2015). 
102 Dotiwala, F. et al. Killer lymphocytes use granulysin, perforin and granzymes to kill 
intracellular parasites. Nat. Med. 22, 210-216 (2016). 
103 Chiusolo, V. et al. Granzyme B enters the mitochondria in a Sam50-, Tim22- and 
mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 24, 747-758 (2017). 
104 Berke, G. The cytolytic T lymphocyte and its mode of action. Immunol.Lett. 20, 169-
178 (1989). 
105 Berke, G. T-cell-mediated cytotoxicity. Curr. Opin. Immunol. 3, 320-325 (1991). 
106 MacLennan, I. C. M., Gotch, F. M. & Golstein, P. Limited specific T-cell mediated 
cytolysis in the absence of extracellular Ca++. Immunology 39, 109-117 (1980). 
107 Tirosh, R. & Berke, G. T lymphocyte-mediated cytolysis as an excitatory process of the 
target. I. Evidence that the target may be the site of Ca++ action. Cell. Immunol. 95, 113-123 
(1985). 
108 Trenn, G., Takayama, H. & Sitkovsky, M. V. Exocytosis of cytolytic granules may not 
be required for target cell lysis by cytotoxic T-lymphocytes. Nature 330, 72-74 (1987). 
 22
109 Ostergaard, H. L., Kane, K. P., Mescher, M. F. & Clark, W. R. Cytotoxic T lymphocyte 
mediated lysis without release of serine esterase. Nature 330, 71-72 (1987). 
110 Young, J. D.-E., Clark, W. R., Liu, C.-C. & Cohn, Z. A. A calcium- and perforin-
independent pathway of killing mediated by murine cytolytic lymphocytes. J. Exp. Med. 166, 
1894-1899 (1987). 
111 Golstein, P. Cytotoxic-T-cell melodrama. Nature 327, 12 (1987). 
112 Conzelmann, A., Corthésy, P., Cianfriglia, M., Silva, A. & Nabholz, M. Hybrids between 
rat lymphoma and mouse T cells with inducible cytolytic activity. Nature 298, 170-172 
(1982). 
113 Golstein, P., Mattéi, M.-G., Foa, C. & Luciani, M.-F. in Apoptosis and the Immune 
Response (ed C.D. Gregory) 143-168 (John Wiley and Sons, Inc., 1995). 
114 Rouvier, E., Luciani, M.-F. & Golstein, P. Fas involvement in Ca++-independent T cell-
mediated cytotoxicity. J. Exp. Med. 177, 195-200 (1993). 
115 Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. & Nagata, S. 
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates 
apoptosis. Nature 356, 314-317 (1992). 
116 Yonehara, S., Ishii, A. & Yonehara, M. A cell-killing monoclonal antibody ( Anti-Fas ) to 
a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. 
Med. 169, 1747-1756 (1989). 
117 Trauth, B. C. et al. Monoclonal antibody-mediated tumor regression by induction of 
apoptosis. Science 245, 301-305 (1989). 
118 Kägi, D. et al. Fas and perforin pathways as major mechanisms of T cell-mediated 
cytotoxicity. Science 265, 528-530 (1994). 
119 Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T-cell cytotoxicity is 
mediated through perforin and Fas lytic pathways. Nature 370, 650-652 (1994). 
120 Walsh, C. M. et al. Immune function in mice lacking the perforin gene. Proc. Natl 
Acad. Sci. U S A. 91, 10854-10858 (1994). 
121 Kojima, H. et al. Two distinct pathways of specific killing revealed by perforin mutant 
cytotoxic T lymphocytes. Immunity. 1, 357-364 (1994). 
122 Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of 
the Fas ligand : a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 
(1993). 
 23
123 Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995). 
124 Krammer, P. H. CD95's deadly mission in the immune system. Nature 407, 789-795 
(2000). 
125 Glimcher, L. H., Townsend, M. J., Sullivan, B. M. & Lord, G. M. Recent developments 
in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4, 900-911 
(2004). 
126 Man, K. & Kallies, A. Synchronizing transcriptional control of T cell metabolism and 
function. Nat. Rev. Immunol. 15, 574-584 (2015). 
127 Xin, A. et al. A molecular threshold for effector CD8(+) T cell differentiation controlled 
by transcription factors Blimp-1 and T-bet. Nat. Immunol. 17, 422-432 (2016). 
128 Ahrends, T. et al. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program 
Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. 
Immunity 47, 848-861 e845 (2017). 
129 Burkhardt, J. K., Hester, S., Lapham, C. K. & Argon, Y. The lytic granules of natural 
killer cells are dual-function organelles combining secretory and pre-lysosomal 
compartments. J. Cell Biol. 111, 2327-2340 (1990). 
130 Peters, P. J. et al. Cytotoxic T lymphocyte granules are secretory lysosomes, 
containing both perforin and granzymes. J. Exp. Med. 173, 1099-1109 (1991). 
131 Stepp, S. E. et al. Perforin gene defects in familial hemophagocytic 
lymphohistiocytosis. Science 286, 1957-1959 (1999). 
132 Pachlopnik Schmid, J. et al. Inherited defects in lymphocyte cytotoxic activity. 
Immunol. Rev. 235, 10-23, doi:IMR890 (2010). 
133 Poenie, M., Tsien, R. Y. & Schmitt-Verhulst, A.-M. Sequential activation and lethal hit 
measured by ( Ca++)i in individual cytolytic T cells and targets. EMBO J. 6, 2223-2232 (1987). 
134 Bykovskaya, S. N., Rytenko, A. N., Rauschenbach, M. O. & Bykovsky, A. F. 
Ultrastructural alteration of cytolytic T lymphocytes following their interaction with target 
cells. I. Hypertrophy and change of orientation of the Golgi apparatus. Cell. Immunol. 40, 
164-174 (1978). 
135 Geiger, B., Rosen, D. & Berke, G. Spatial relationships of microtubule-organizing 
centers and the contact area of cytotoxic T lymphocytes and target cells. J. Cell Biol. 95, 137-
143 (1982). 
 24
136 Kupfer, A., Dennert, G. & Singer, S. J. Polarization of the Golgi apparatus and the 
microtubule-organizing center within cloned natural killer cells bound to their targets. Proc. 
Natl Acad. Sci. U S A. 80, 7224-7228 (1983). 
137 Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-dimensional 
segregation of supramolecular activation clusters in T cells. Nature 395, 82-86 (1998). 
138 Stinchcombe, J. C., Bossi, G., Booth, S. & Griffiths, G. M. The immunological synapse 
of CTL contains a secretory domain and membrane bridges. Immunity 15, 751-761 (2001). 
139 Stinchcombe, J. C., Majorovits, E., Bossi, G., Fuller, S. & Griffiths, G. M. Centrosome 
polarization delivers secretory granules to the immunological synapse. Nature 443, 462-465 
(2006). 
140 Lopez, J. A. et al. Perforin forms transient pores on the target cell plasma membrane 
to facilitate rapid access of granzymes during killer cell attack. Blood 121, 2659-2668 (2013). 
141 Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. 
Science 282, 121-125 (1998). 
142 Ochoa, M. T. et al. T-cell release of granulysin contributes to host defense in leprosy. 
Nat. Med. 7, 174-179 (2001). 
143 Stegelmann, F. et al. Coordinate expression of CC chemokine ligand 5, granulysin, and 
perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium 
tuberculosis. J. Immunol. 175, 7474-7483 (2005). 
144 Dotiwala, F. et al. Granzyme B Disrupts Central Metabolism and Protein Synthesis in 
Bacteria to Promote an Immune Cell Death Program. Cell 171, 1125-1137 e1111 (2017). 
145 Tanaka, M., Itai, T., Adachi, M. & Nagata, S. Downregulation of Fas ligand by 
shedding. Nat.Med. 4, 31-36 (1998). 
146 Bossi, G. & Griffiths, G. M. Degranulation plays an essential part in regulating cell 
surface expression of Fas ligand in T cells and natural killer cells. Nat.Med. 5, 90-96 (1999). 
147 Zuccato, E. et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-
ubiquitylation and phosphorylation. J. Cell Sci. 120, 191-199 (2007). 
148 Martinez-Lorenzo, M. J. et al. Activated human T cells release bioactive Fas ligand and 
APO2 ligand in microvesicles. J. Immunol. 163, 1274-1281 (1999). 
149 Lee, J., Dieckmann, N. M., Edgar, J., Griffiths, G. M. & Siegel, R. M. Fas Ligand localizes 
to intraluminal vesicles within NK cell cytolytic granules, delivering membrane-bound FasL to 
the immune synapse. Immunity, Inflammation and Disease. in press (2018).  
 25
150 Schneider, P. et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J.Biol. 
Chem. 272, 18827-18833 (1997). 
151 Boldin, M. P. et al. A novel protein that interacts with the death domains of Fas/APO1 
contains a sequence motif related to the death domain. J. Biol. Chem. 270, 7795-7798 
(1995). 
152 Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is 
recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827 
(1996). 
153 Hueber, A. O., Bernard, A. M., Herincs, Z., Couzinet, A. & He, H. T. An essential role 
for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. 
EMBO Rep. 3, 190-196 (2002). 
154 Rossin, A. et al. Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates 
Fas stability. Cell Death Differ. 22, 643-653 (2015). 
155 Desbarats, J. & Newell, M. K. Fas engagement accelerates liver regeneration after 
partial hepatectomy. Nat.Med. 6, 920-923 (2000). 
156 Peter, M. E. et al. The CD95 receptor: apoptosis revisited. Cell 129, 447-450 (2007). 
157 Yamada, A., Arakaki, R., Saito, M., Kudo, Y. & Ishimaru, N. Dual Role of Fas/FasL-
Mediated Signal in Peripheral Immune Tolerance. Front. Immunol. 8, 403 (2017). 
158 Le Gallo, M., Poissonnier, A., Blanco, P. & Legembre, P. CD95/Fas, Non-Apoptotic 
Signaling Pathways, and Kinases. Front. Immunol. 8, 1216 (2017). 
159 Rieux-Laucat, F. et al. Mutations in Fas associated with human lymphoproliferative 
syndrome and autoimmunity. Science 268, 1347-1349 (1995). 
160 Balomenos, D., Shokri, R., Daszkiewicz, L., Vazquez-Mateo, C. & Martinez, A. C. On 
How Fas Apoptosis-Independent Pathways Drive T Cell Hyperproliferation and 
Lymphadenopathy in lpr Mice. Front. Immunol. 8, 237 (2017). 
161 Van den Broek, M. F. et al. Decreased tumor surveillance in perforin-deficient mice. J. 
Exp. Med. 184, 1781-1790 (1996). 
162 Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of 
spontaneous lymphoma. J. Exp. Med. 192, 755-760 (2000). 
163 Rosenberg, S. A. & Lotze, M. T. Cancer immunotherapy using interleukin-2 and 
interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4, 681-709 (1986). 
 26
164 Brunet, J.-F. et al. A new member of the immunoglobulin superfamily - CTLA-4. 
Nature 328, 267-270 (1987). 
165 Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel 
member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 
11, 3887-3895 (1992). 
166 Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice 
deficient in Ctla-4. Science 270, 985-988 (1995). 
167 Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal 
multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. 
Immunity  3, 541-547 (1995). 
168 Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous 
germline mutations in CTLA4. Science 345, 1623-1627 (2014). 
169 Schubert, D. et al. Autosomal dominant immune dysregulation syndrome in humans 
with CTLA4 mutations. Nat. Med. 20, 1410-1416 (2014). 
170 Nishimura, H., Minato, N., Nakano, T. & Honjo, T. Immunological studies on PD-1 
deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 
10, 1563-1572 (1998). 
171 Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like 
autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying 
immunoreceptor. Immunity 11, 141-151 (1999). 
172 Nishimura, H. & Honjo, T. PD-1: an inhibitory immunoreceptor involved in peripheral 
tolerance. Trends Immunol. 22, 265-268 (2001). 
173 Wei, S. C. et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 
Checkpoint Blockade. Cell 170, 1120-1133 (2017). 
174 Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. 
Rev. Immunol. 15, 486-499 (2015). 
175 Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by 
CTLA-4 blockade. Science 271, 1734-1736 (1996). 
176 Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune 
system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. U S A. 99, 12293-
12297 (2002). 
 27
177 Blank, C. et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell 
receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64, 1140-1145 (2004). 
178 Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic 
melanoma. N. Engl. J. Med. 363, 711-723 (2010). 
179 Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in 
cancer. N. Engl. J. Med. 366, 2443-2454 (2012). 
180 Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in 
melanoma. N. Engl. J. Med. 369, 134-144 (2013). 
181 Sharpe, A. H. Introduction to checkpoint inhibitors and cancer immunotherapy. 
Immunol. Rev. 276, 5-8 (2017). 
182 Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. 
Rev. Immunol. 18, 91-104 (2018). 
183 Dyck, L. & Mills, K. H. G. Immune checkpoints and their inhibition in cancer and 
infectious diseases. Eur. J. Immunol. 47, 765-779 (2017). 
184 Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. 
Exp. Med. 174, 561-569 (1991). 
185 Adams, A. B., Ford, M. L. & Larsen, C. P. Costimulation Blockade in Autoimmunity and 
Transplantation: The CD28 Pathway. J. Immunol. 197, 2045-2050 (2016). 
186 Ceeraz, S., Nowak, E. C., Burns, C. M. & Noelle, R. J. Immune checkpoint receptors in 
regulating immune reactivity in rheumatic disease. Arthritis Res. Ther. 16, 469 (2014). 
187 Lin, H. et al. Review of CTLA4Ig use for allograft immunosuppression. Transplant.Proc. 
26, 3200-3201 (1994). 
188 Huber, M., Kemmner, S., Renders, L. & Heemann, U. Should belatacept be the 
centrepiece of renal transplantation? Nephrol. Dial. Transplant. 31, 1995-2002 (2016). 
189 Sandigursky, S., Silverman, G. J. & Mor, A. Targeting the programmed cell death-1 
pathway in rheumatoid arthritis. Autoimmun. Rev. 16, 767-773 (2017). 
190 June, C. H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117, 1466-
1476 (2007). 
191 Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor 
chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. 
Sci. U S A. 86, 10024-10028 (1989). 
 28
192 Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of 
cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding 
domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. 
Natl Acad. Sci. U S A. 90, 720-724 (1993). 
193 Gross, G. & Eshhar, Z. Therapeutic Potential of T Cell Chimeric Antigen Receptors 
(CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. 
Annu. Rev. Pharmacol. Toxicol. 56, 59-83 (2016). 
194 Schmidt, H. et al. Effector granules in human T lymphocytes: proteomic evidence for 
two distinct species of cytotoxic effector vesicles. J. Proteome Res. 10, 1603-1620 (2011). 
 
Acknowledgements 
P.G. thanks Association pour la Recherche sur le Cancer for support, and Institut National de 
la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, and Aix 
Marseille University for institutional support to the CIML. G.M.G. thanks the Wellcome 
Trust for research funding (grants 103930 and 100140). The authors thank all past and present 
members of their laboratories for their contribution to this research. 
 
Author contributions 
Both authors researched data for the article, discussed its content, and wrote, reviewed and 
edited the manuscript before submission. 
 
Competing interests statement 
The authors declare no competing interests. 
 
Publisher's note 
Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations. 
 
 29
Figure 1 | Timeline of the history of research on cytotoxic T cells (CTLs). CAR T cell, 
chimeric antigen receptor-bearing T cell; CTLA4, cytotoxic T lymphocyte antigen 4; PD1, 
programmed cell death protein 1. 
 
Figure 2 | Chronological scheme of research on the mechanisms of CTL-mediated 
cytotoxicity. A cytotoxic T lymphocyte (CTL) recognizes through its T cell receptor (TCR) 
an antigen–MHC complex on a target cell. This can trigger the migration of granules towards 
the region of the CTL facing the target cell. The figure shows a simplified representation of 
granules, which are known to contain both FAS ligand (FASL) on intraluminal vesicles and 
perforin and granzymes149. Alternatively, other studies have suggested that FASL is contained 
in distinct granules for perforin and granzymes194. Granules within the CTL open into the 
intercellular cleft (the immune synapse) upon CTL activation, where they release their 
contents. This can lead to two distinct mechanisms of cell death in the target cell. In one 
mechanism, FASL engages FAS at the target cell membrane, leading, through FAS-associated 
death domain protein (FADD), to the activation of caspase 8. This leads, in turn, to the 
cleavage and thus activation of caspase 3 and subsequent apoptosis. In the other mechanism, 
perforin opens a channel in the target cell membrane, through which granzyme B enters the 
cytosol and activates caspase 3, also leading to apoptosis. Less frequent, non-apoptotic types 
of cell death have also been described following encounters with CTLs. The colour scale 
corresponds to the date of publication of discovery or use of the corresponding moiety. Note 
that most of the studies on the perforin–granzyme-mediated mechanism of cell death preceded 
those on the FAS-mediated pathway.  
 
Glossary 
51Cr release assay 
Evaluates the percentage of target cells that are lysed by cytotoxic T cells by measuring the 
proportion of radioactivity released from pre-labelled target cells. 
Allogeneic 
Describes tissues or cells that are of the same species but are not genetically identical. 
Antibody plaque formation 
The ability of haemolytic antibody-forming lymphocytes to form plaques of lysed red blood 
cells in agar after being subjected to, for example, cytotoxic T cells. 
Clonogenic assays 
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Determine the percentage of cells that are able to form colonies in vitro after being subjected 
to, for example, cytotoxic T cells. 
Congenic 
Describes tissues or cells that genetically differ by only one chromosomal region. 
Haemophagocytic lymphohistiocytosis 
(HLH). A human autosomal recessive disorder that results from mutation of one of five genes, 
including the gene encoding perforin, and that leads to T cell hyperproliferation. 
Homograft 
A graft from a donor of the same species as the recipient. 
lpr mice 
Mice bearing the lpr mutation of the Fas gene, leading to a lymphoproliferative phenotype. 
Syngeneic 
Describes tissues or cells that are genetically identical. 
Xenogeneic 
Describes tissues or cells that are of different species. 
 
Online only 
Subject categories 
Biological sciences / Immunology / Lymphocytes / T cells / CD8-positive T cells / Cytotoxic 
T cells 
[URI /631/250/1619/554/1834/1269] 
Biological sciences / Immunology / Immunotherapy 
[URI /631/250/251] 
 
ToC blurb 
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